A Phase 3 interventional study of GC5107 in Immunologic Deficiency Syndromes, sponsored by Green Cross Corporation. Completed at 20 sites in 2 countries. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-12-09.
Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 23rd largest by enrollment of the 77 interventional ones that give a count, is one of 10 that started in 2016, is one of 8 in phase 3, and was the 85th registered.
204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.
Browse Immunologic Deficiency Syndromes studies →27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–120 · Healthy volunteers
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 4+
Monica Bhatia · Sites in United States
Ages 3 mo–26 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 1 mo–25 yrs
Washington University School of Medicine · Sites in United States
Ages 8+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 40 · Phase 3 10 · Phase 4 2
First in 1977; this study’s year is marked. 10 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 30 across 123 interventional studies indexed under Immunologic Deficiency Syndromes.
Median enrollment 28 across the 77 interventional studies, 142 across the 45 observational. Of the 83 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Green Cross Corporation, one of the names counted as GC Biopharma Corp.. Under that name alone:
Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
GC Biopharma Corp. has 2 studies filed under Immunologic Deficiency Syndromes — fewer than ten, so there is no comparison to draw.
9 of the studies in Immunologic Deficiency Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06689800Washington University School of MedicineLet's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy | 2026-11-30 |
| NCT02356653Children's Hospital of PhiladelphiaExpanded Access Protocol Using CD3+/CD19+ Depleted PBSC | 2027-01 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05333471National Institute of Allergy and Infectious Diseases (NIAID)Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | 2027-03-01 |
| NCT04554914Pierre Fabre MedicamentA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in subjects with Primary Humoral Immunodeficiency (PHID).
This was a prospective, open-label, single-arm, historically controlled, multicenter phase 3 study measuring the safety, efficacy and pharmacokinetics and tolerability of GC5107 in subjects with Primary Humoral Immunodeficiency disease (PHID).
Subjects received intravenous infusions of the investigational product at the same dose and interval as used for their previous Immunoglobulin intravenous (IVIG) maintenance therapy. GC5107 was administered every 21 or 28 days for a period of 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GC5107 Immune globulin intravenous (human) solution, 10% liquid
Biological: GC5107
GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
Also known as: IGIV, Immune globulin intravenous (human) solution, 10% liquid
The Incidence of Acute Serious Bacterial Infections (SBI)
The incidence of acute serious bacterial infections (aSBIs) meeting FDA guidance criteria, which includes bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscesses, and osteomyelitis/septic arthritis. Efficacy data is evaluated by comparing the frequency of acute serious bacterial infections per subject per year according to the FDA guideline of an upper one-sided 99% confidence limit \< 1.0 per subject per year.
Time frame: One year
The Proportion of Infusions With Temporally Associated Adverse Events (TAAEs) That Occur Within 72 Hours Following an Infusion of Test Product
The proportion of infusions with temporally associated adverse events occurring during or within 72 hours following infusion, whether or not they were thought to be related to GC5107
Time frame: Within 72 hours after an infusion of GC5107
The Incidence of Infections Other Than Acute Serious Bacterial Infections
Time frame: One year
The Number of Days Missed From Work/School/Kindergarten/Daycare, or Days Unable to Perform Normal Daily Activities Due to Infections
Based on the total number of days missed from work/school/kindergarten/daycare or days unable to perform normal daily activities due to infections for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit - first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
Time frame: One year
The Number of Days of Unscheduled Physician Visits Due to Infections
Based on the total number of days of unscheduled physician visits due to infections for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit - first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
Time frame: One year
The Number of Days of Hospitalizations Due to Infections
Subject with no experience of specific event will be included in the analysis as zero incidence, zero day, or zero time duration. The mean and SD will be calculated weighting for the duration of data available for each subject.
Time frame: One year
The Number of Days of Intravenous (IV) Therapeutic Antibiotics
Based on the total number of days of IV therapeutic antibiotics for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit -first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
Time frame: One year
The Number of Days of Oral Therapeutic Antibiotics
Based on the total number of days of oral (PO) therapeutic antibiotics for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit - first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
Time frame: One year
| Milestone | 28-day Schedule | 21-day Schedule |
|---|---|---|
| Started | 29 | 20 |
| Completed | 24 | 19 |
| Not completed | 5 | 1 |
The incidence of acute serious bacterial infections (aSBIs) meeting FDA guidance criteria, which includes bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscesses, and osteomyelitis/septic arthritis. Efficacy data is evaluated by comparing the frequency of acute serious bacterial infections per subject per year according to the FDA guideline of an upper one-sided 99% confidence limit \< 1.0 per subject per year.
| Number of events per patient per year | 28-day Schedule | 21-day Schedule | Total |
|---|---|---|---|
| The Incidence of Acute Serious Bacterial Infections (SBI) | 0.04 (NA to 0.35) | 0 (NA to NA) | 0.02 (NA to 0.21) |
The proportion of infusions with temporally associated adverse events occurring during or within 72 hours following infusion, whether or not they were thought to be related to GC5107
| Proportion of infusion with TAAEs | 28-day Schedule | 21-day Schedule | Total |
|---|---|---|---|
| The Proportion of Infusions With Temporally Associated Adverse Events (TAAEs) That Occur Within 72 Hours Following an Infusion of Test Product | 0.31 (NA to 0.40) | 0.16 (NA to 0.22) | 0.24 (NA to 0.31) |
| Numberof infections per patient per year | 28-day Schedule | 21-day Schedule | Total |
|---|---|---|---|
| The Incidence of Infections Other Than Acute Serious Bacterial Infections | 2.4 | 3.6 | 2.9 |
Based on the total number of days missed from work/school/kindergarten/daycare or days unable to perform normal daily activities due to infections for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit - first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
| Days | 28-day Schedule | 21-day Schedule | Total |
|---|---|---|---|
| The Number of Days Missed From Work/School/Kindergarten/Daycare, or Days Unable to Perform Normal Daily Activities Due to Infections | 2.9 ± 4.20 | 12.7 ± 26.11 | 7.1 ± 18.04 |
Based on the total number of days of unscheduled physician visits due to infections for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit - first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
| Days | 28-day Schedule | 21-day Schedule | GC5107 IVIG 10% |
|---|---|---|---|
| The Number of Days of Unscheduled Physician Visits Due to Infections | 2.3 ± 4.56 | 2.4 ± 2.25 | 2.3 ± 3.75 |
Subject with no experience of specific event will be included in the analysis as zero incidence, zero day, or zero time duration. The mean and SD will be calculated weighting for the duration of data available for each subject.
| Days | 28-day Schedule | 21-day Schedule | Total |
|---|---|---|---|
| The Number of Days of Hospitalizations Due to Infections | 0.1 ± 0.57 | 0.1 ± 0.46 | 0.1 ± 0.53 |
Based on the total number of days of IV therapeutic antibiotics for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit -first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
| Days | 28-day Schedule | 21-day Schedule | GC5107 IVIG 10% |
|---|---|---|---|
| The Number of Days of Intravenous (IV) Therapeutic Antibiotics | 0.1 ± 0.57 | 0.0 ± 0.00 | 0.1 ± 0.44 |
Based on the total number of days of oral (PO) therapeutic antibiotics for each subject. Mean and SD are calculated based on weighting for the duration of data available for each subject, where duration is defined as (date of last visit - first infusion date + 1) for subjects who complete the study; and defined as (date of withdrawal - first infusion date + 1) for subjects who withdraw from the study.
| Days | 28-day Schedule | 21-day Schedule | GC5107 IVIG 10% |
|---|---|---|---|
| The Number of Days of Oral Therapeutic Antibiotics | 13.3 ± 24.50 | 13.1 ± 18.38 | 13.2 ± 22.09 |
Collected over One year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GC5107 IVIG 10% | 0/49 (0%) | 4/49 (8.2%) | 49/49 (100%) |
| Event | GC5107 IVIG 10% |
|---|---|
| InfluenzaInfections and infestations | 1/49 |
| Acute urticariaSkin and subcutaneous tissue disorders | 1/49 |
| ST elevation myocardial infarctionCardiac disorders | 1/49 |
| Bacterial pneumoniaInfections and infestations | 1/49 |
| Squamous cell carcinoma of base of tongueNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/49 |
| Event | GC5107 IVIG 10% |
|---|---|
| HeadacheNervous system disorders | 28/49 |
| NauseaGastrointestinal disorders | 20/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/49 |
| FatigueGeneral disorders | 13/49 |
| PyrexiaGeneral disorders | 13/49 |
| SinusitisInfections and infestations | 13/49 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 11/49 |
| DiarrhoeaGastrointestinal disorders | 9/49 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 9/49 |
| Abdominal pain upperGastrointestinal disorders | 8/49 |
| Age, Continuous(years) | 28-day Infusion | 21-day Infusion | Total |
|---|---|---|---|
| Mean | 41.5 ± 21.7 | 30.7 ± 23.2 | 37.1 ± 22.7 |
| Sex: Female, Male(Participants) | 28-day Infusion | 21-day Infusion | Total |
|---|---|---|---|
| Female | 13 | 8 | 21 |
| Male | 16 | 12 | 28 |
| Race/Ethnicity, Customized(Participants) | 28-day Infusion | 21-day Infusion | Total |
|---|---|---|---|
| White | 28 | 19 | 47 |
| Other | 1 | 1 | 2 |
| Region of Enrollment(Participants) | 28-day Infusion | 21-day Infusion | Total |
|---|---|---|---|
| Canada | 11 | 2 | 13 |
| United States | 18 | 18 | 36 |
| Duration since first IVIG infusion(years) | 28-day Infusion | 21-day Infusion | Total |
|---|---|---|---|
| Mean | 8.8 ± 8.3 | 8.8 ± 6.7 | 8.8 ± 7.6 |
| IVIG dose prior to enrollment(mg/kg) | 28-day Infusion | 21-day Infusion | Total |
|---|---|---|---|
| Mean | 501.2 ± 94.0 | 592.7 ± 135.9 | 538.5 ± 120.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in Jul 2019, 33 months.
Results were first posted in Oct 2022, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Immunologic Deficiency Syndromes →